Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Michelle Toker; Jose A. Jaller; Caroline Delbourgo Patton; Benedict Wu

doi:10.1111/pde.15505

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Michelle Toker, Jose A. Jaller, Caroline Delbourgo Patton, Benedict Wu

Research output: Contribution to journal › Review article › peer-review

Abstract

Cutaneous adverse events are commonly reported in adult patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs); however, little is known about the cutaneous reactions in children receiving TKIs for CML. As pediatric patients may require lifelong TKI therapy, it is essential to understand the wide range of potential cutaneous toxicities. We examined all case studies, cohort studies, and clinical trials in PubMed/MEDLINE and Embase that reported cutaneous reactions to first-, second-, and third-generation TKIs in children 18 years or younger with CML. This review article focuses on the TKI drug types and doses, patient demographic characteristics, features of skin reactions, and clinical outcomes.

Original language	English (US)
Pages (from-to)	169-176
Number of pages	8
Journal	Pediatric Dermatology
Volume	41
Issue number	1
DOIs	https://doi.org/10.1111/pde.15505
State	Published - Jan 1 2024

Keywords

chemotoxicity
chronic myeloid leukemia (CML)
cutaneous adverse reactions
pediatrics
tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Dermatology

Access to Document

10.1111/pde.15505

Cite this

@article{f104f7e8d70c4b078661cfff07ba41cf,

title = "Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia",

abstract = "Cutaneous adverse events are commonly reported in adult patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs); however, little is known about the cutaneous reactions in children receiving TKIs for CML. As pediatric patients may require lifelong TKI therapy, it is essential to understand the wide range of potential cutaneous toxicities. We examined all case studies, cohort studies, and clinical trials in PubMed/MEDLINE and Embase that reported cutaneous reactions to first-, second-, and third-generation TKIs in children 18 years or younger with CML. This review article focuses on the TKI drug types and doses, patient demographic characteristics, features of skin reactions, and clinical outcomes.",

keywords = "chemotoxicity, chronic myeloid leukemia (CML), cutaneous adverse reactions, pediatrics, tyrosine kinase inhibitors (TKIs)",

author = "Michelle Toker and Jaller, {Jose A.} and {Delbourgo Patton}, Caroline and Benedict Wu",

note = "Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2024",

month = jan,

day = "1",

doi = "10.1111/pde.15505",

language = "English (US)",

volume = "41",

pages = "169--176",

journal = "Pediatric Dermatology",

issn = "0736-8046",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

AU - Toker, Michelle

AU - Jaller, Jose A.

AU - Delbourgo Patton, Caroline

AU - Wu, Benedict

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Cutaneous adverse events are commonly reported in adult patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs); however, little is known about the cutaneous reactions in children receiving TKIs for CML. As pediatric patients may require lifelong TKI therapy, it is essential to understand the wide range of potential cutaneous toxicities. We examined all case studies, cohort studies, and clinical trials in PubMed/MEDLINE and Embase that reported cutaneous reactions to first-, second-, and third-generation TKIs in children 18 years or younger with CML. This review article focuses on the TKI drug types and doses, patient demographic characteristics, features of skin reactions, and clinical outcomes.

AB - Cutaneous adverse events are commonly reported in adult patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs); however, little is known about the cutaneous reactions in children receiving TKIs for CML. As pediatric patients may require lifelong TKI therapy, it is essential to understand the wide range of potential cutaneous toxicities. We examined all case studies, cohort studies, and clinical trials in PubMed/MEDLINE and Embase that reported cutaneous reactions to first-, second-, and third-generation TKIs in children 18 years or younger with CML. This review article focuses on the TKI drug types and doses, patient demographic characteristics, features of skin reactions, and clinical outcomes.

KW - chemotoxicity

KW - chronic myeloid leukemia (CML)

KW - cutaneous adverse reactions

KW - pediatrics

KW - tyrosine kinase inhibitors (TKIs)

UR - http://www.scopus.com/inward/record.url?scp=85180918804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85180918804&partnerID=8YFLogxK

U2 - 10.1111/pde.15505

DO - 10.1111/pde.15505

M3 - Review article

AN - SCOPUS:85180918804

SN - 0736-8046

VL - 41

SP - 169

EP - 176

JO - Pediatric Dermatology

JF - Pediatric Dermatology

IS - 1

ER -

Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this